Keywords: Watson Pharma, Actavis, Fitch Rating, Debt funding, USA

Fitch puts Watson on rating watch Negative on planned acquisition of Actavis

Article | 26 April 2012

Print This

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings, including the 'BBB' Issuer Default ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in